CVRx, Inc. announced the enrollment of the first patient in the BENEFIT-HF trial, a major study testing Barostim therapy in a larger heart failure patient group. The trial will enroll 2,500 patients across 150 centers in the US and Germany, aiming to evaluate mortality and heart failure events. If successful, it could triple the eligible patient population for Barostim, broadening access to this FDA-approved neuromodulation device. The trial is expected to run through 2032, potentially strengthening Barostim's role in heart failure treatment.
A new study found that adults with alcohol use disorder (AUD) who started treatment with GLP-1 receptor agonists like semaglutide and tirzepatide had significantly fewer alcohol-related hospitalizations compared to those on other diabetes or obesity ...
D.R. Horton reported Q3 earnings per share of $3.20, beating estimates, and revenues of $9.23 billion, slightly above expectations. Goldman Sachs raised its price target to $190 and maintained a "Buy" rating, signaling strong growth potential. Despit...
Interactive Brokers reported a strong Q2 with diluted EPS of $0.69 and net revenues of $1.90 billion, both exceeding analyst expectations. The company saw a 34% increase in client accounts and a 40% rise in client equity, driven by higher trading act...
United Rentals is set to report its Q2 2026 earnings on July 22, with analysts forecasting an 11.5% rise in earnings per share to $11.67 and a 7.3% increase in revenue to $4.23 billion. The growth is driven by strong rental demand and efficient equip...
Paladin Energy successfully completed the ramp-up of its Langer Heinrich Mine, producing 4.82 million pounds of uranium oxide (U₃O₈) in FY2026, exceeding guidance. Sales totaled 4.35 million pounds at an average price of $70.6/lb. The Patterson Lake ...
